Alterity Therapeutics (NASDAQ:ATHE) Trading Up 1% – Time to Buy?

Alterity Therapeutics Limited (NASDAQ:ATHE) traded up 1% on Tuesday . The stock traded as high as $3.72 and last traded at $3.58. 4,098 shares changed hands during trading, a decline of 97% from the average session volume of 152,782 shares. The stock had previously closed at $3.54.

Analysts Set New Price Targets

ATHE has been the subject of a number of research reports. Maxim Group increased their price objective on Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. Benchmark lowered shares of Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a research note on Monday, February 3rd.

Alterity Therapeutics Stock Performance

The stock has a 50-day moving average of $3.89 and a two-hundred day moving average of $2.50.

Hedge Funds Weigh In On Alterity Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. purchased a new stake in Alterity Therapeutics during the 4th quarter valued at about $108,000. BNP Paribas Financial Markets bought a new position in shares of Alterity Therapeutics in the fourth quarter worth approximately $29,000. Finally, HB Wealth Management LLC grew its holdings in shares of Alterity Therapeutics by 34.1% during the fourth quarter. HB Wealth Management LLC now owns 31,883 shares of the company’s stock valued at $110,000 after buying an additional 8,100 shares during the last quarter. 2.14% of the stock is currently owned by institutional investors.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.